Par Pharmaceutical Wins On Invalidity In Ultram ER Litigation
Intends to review its options with respect to tramadol ER ANDA
Par Pharmaceutical has announced that the US District Court for the District of Delaware has ruled in favor of Par in its challenge of Purdue’s patents relating to extended-release tramadol, which are listed in the Orange Book for Ortho-McNeil’s Ultram ER product.
Par earlier announced that it had filed an Abbreviated New Drug Application (ANDA) seeking marketing approval for generic extended-release tramadol, and that it was the first-filed ANDA with respect to the Ultram ER product.
Par currently has tentative approval on two of the three strengths (100mg and 200mg) of tramadol ER. The company intends to review its options with respect to its tramadol ER ANDA.
Related Insight
Suppliers Directory
Girindus - Oligonucleotide, Small Molecule, and Radiolabeled Active Pharmaceutical Ingredients
Girindus is a customer-driven company offering pharmaceutical clients comprehensive skills, ranging from process development, analytical method development, radiolabeling, cGMP compliant scale-up and manufacturing of active ingredients, as well as regulatory support.
Suppliers
BioBuffer Solutions - Biopharm/Biotech Buffers and Reagents
BioBuffer Solutions is a manufacturer of biological buffers and laboratory reagents intended for use in the biopharm and biotech markets. The staff at BioBuffer Solutions has over 15 years of experience in the manufacturing and quality management of these buffers and reagents. We offer fully traceable custom buffers, reagents and solutions.
Suppliers
Anoto - Providing Unique Technology for Digital Pen and Paper
Founded in 1999, Anoto Group AB is the pioneering leader of Digital Pen & Paper technology that optimises paper-based processes by rapidly and reliably converting handwritten text from paper to digital media.
Suppliers
BioPartners - Developing Biologics, Delivering Patient Care
Established in 2000, Biopartners' aim is to be a leader in developing and commercialising innovative formulations and novel delivery systems of first-generation biopharmaceuticals for which there are substantial unmet medical/patients' needs.
Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Intelligence
Set-up Reduction in Biotech: When Every Minute Counts
Published by TBM Consulting Group
White Papers
DXA Services
Published by CoreLab Partners
White Papers
PhenomTM Pro Suite
Published by Phenom World
White Papers
Big Pharma R&D – thinking big, acting small
Published by Kinapse
White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.